Teva Pharma (TEVA) Misses Q1 EPS by 15c, Revenue Beats, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Teva Reports First Quarter 2023 Financial Results and Reaffirms 2023 Non-GAAP Outlook
May 10, 2023 7:00 AM EDTTEL AVIV, Israel--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended March 31, 2023.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230510005122/en/
Revenues of $3.7 billion GAAP loss per share of $0.18 Non-GAAP diluted EPS of $0.40 Cash flow used in operating activities of $145 million Free cash flow... More